Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Avadomide monotherapy in relapsed/refractory DLBCL: safety, efficacy, and a predictive gene classifier
Cecilia Carpio, Réda Bouabdallah, Loïc Ysebaert, et al.
Blood (2020) Vol. 135, Iss. 13, pp. 996-1007
Open Access | Times Cited: 61

Showing 1-25 of 61 citing articles:

Targeted protein degradation: advances in drug discovery and clinical practice
Guangcai Zhong, Xiaoyu Chang, Weilin Xie, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 19
Cancer therapies based on targeted protein degradation — lessons learned with lenalidomide
Max Jan, Adam S. Sperling, Benjamin L. Ebert
Nature Reviews Clinical Oncology (2021) Vol. 18, Iss. 7, pp. 401-417
Open Access | Times Cited: 101
Molecular mechanisms of thalidomide and its derivatives
Takumi Ito, Hiroshi Handa
Proceedings of the Japan Academy Series B (2020) Vol. 96, Iss. 6, pp. 189-203
Open Access | Times Cited: 86
A proximity biotinylation-based approach to identify protein-E3 ligase interactions induced by PROTACs and molecular glues
Satoshi Yamanaka, Yuto Horiuchi, Saya Matsuoka, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 60
α-KG inhibits tumor growth of diffuse large B-cell lymphoma by inducing ROS and TP53-mediated ferroptosis
Yiqing Cai, Liemei Lv, Tiange Lu, et al.
Cell Death Discovery (2023) Vol. 9, Iss. 1
Open Access | Times Cited: 23
DNA-PKcs: A Targetable Protumorigenic Protein Kinase
Emanuela Dylgjeri, Karen E. Knudsen
Cancer Research (2021) Vol. 82, Iss. 4, pp. 523-533
Open Access | Times Cited: 42
Targeting cereblon in hematologic malignancies
Ota Fuchs
Blood Reviews (2022) Vol. 57, pp. 100994-100994
Open Access | Times Cited: 30
The progress of novel strategies on immune-based therapy in relapsed or refractory diffuse large B-cell lymphoma
Tingxun Lu, Jie Zhang, Zijun Y. Xu‐Monette, et al.
Experimental Hematology and Oncology (2023) Vol. 12, Iss. 1
Open Access | Times Cited: 18
Triggering interferon signaling in T cells with avadomide sensitizes CLL to anti-PD-L1/PD-1 immunotherapy
Nikolaos Ioannou, Patrick R. Hagner, Matt Stokes, et al.
Blood (2020) Vol. 137, Iss. 2, pp. 216-231
Open Access | Times Cited: 44
DNA-PK in human malignant disorders: Mechanisms and implications for pharmacological interventions
Michaela Medová, Matúš Medo, Lusine Hovhannisyan, et al.
Pharmacology & Therapeutics (2020) Vol. 215, pp. 107617-107617
Open Access | Times Cited: 41
Exploiting ubiquitin ligase cereblon as a target for small-molecule compounds in medicine and chemical biology
Takumi Ito, Yuki Yamaguchi, Hiroshi Handa
Cell chemical biology (2021) Vol. 28, Iss. 7, pp. 987-999
Open Access | Times Cited: 40
Blockade of PD-1 and LAG-3 expression on CD8+ T cells promotes the tumoricidal effects of CD8+ T cells
Jiajia Ma, Shufang Yan, Ying Zhao, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 14
The emerging role of targeted protein degradation to treat and study cancer
Maximillian H. Brodermann, Elizabeth Henderson, Rob S. Sellar
The Journal of Pathology (2024) Vol. 263, Iss. 4-5, pp. 403-417
Open Access | Times Cited: 5
Avadomide Induces Degradation of ZMYM2 Fusion Oncoproteins in Hematologic Malignancies
Aline Renneville, Jessica A. Gasser, Daniel E. Grinshpun, et al.
Blood Cancer Discovery (2021) Vol. 2, Iss. 3, pp. 250-265
Open Access | Times Cited: 31
Immunomodulatory Drugs for the Treatment of B Cell Malignancies
Nikolaos Ioannou, Khushi Jain, Alan G. Ramsay
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 16, pp. 8572-8572
Open Access | Times Cited: 31
Amino Acid Metabolism-Related Gene Kynureninase (KYNU) as a Prognostic Predictor and Regulator of Diffuse Large B-Cell Lymphoma
Yu Zhang, Feng Shi, Liemei Lv, et al.
Biochemical Genetics (2025)
Closed Access
An introduction to quantitative systems pharmacology for chemical engineers
R. Abbiati, César Pichardo‐Almarza
Physical Sciences Reviews (2025)
Closed Access
Influence of Vitamin D and Its Analogues in Type-B Lymphomas
Valerio Basile, Alessandro Allegra, Herbert Marini, et al.
Current Oncology (2025) Vol. 32, Iss. 3, pp. 135-135
Open Access
Expression and Clinical Significance of CXCR5 and LAG‐3 on Peripheral Blood CD8+ T Cells in Patients With Diffuse Large B‐Cell Lymphoma
Xi‐Zhe Guo, Yu Guo, Shi‐Xin Wu
The Kaohsiung Journal of Medical Sciences (2025)
Open Access
Investigational drugs for the treatment of diffuse large B-cell lymphoma
Andrea Patriarca, Gianluca Gaïdano
Expert Opinion on Investigational Drugs (2020) Vol. 30, Iss. 1, pp. 25-38
Open Access | Times Cited: 30
Avadomide plus obinutuzumab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (CC-122-NHL-001): a multicentre, dose escalation and expansion phase 1 study
Jean‐Marie Michot, Réda Bouabdallah, Umberto Vitolo, et al.
The Lancet Haematology (2020) Vol. 7, Iss. 9, pp. e649-e659
Open Access | Times Cited: 28
CAR‐T TREK through the lymphoma universe, to boldly go where no other therapy has gone before
Guido Ghilardi, Peter Brændstrup, Elise A. Chong, et al.
British Journal of Haematology (2020) Vol. 193, Iss. 3, pp. 449-465
Open Access | Times Cited: 28
Tumor Microenvironment and Immunotherapy-Based Approaches in Mantle Cell Lymphoma
Khalil Saleh, Morgane Cheminant, David Chiron, et al.
Cancers (2022) Vol. 14, Iss. 13, pp. 3229-3229
Open Access | Times Cited: 17
FPFT-2216, a novel anti-lymphoma compound, induces simultaneous degradation of IKZF1/3 and CK1α to activate p53 and inhibit NF-κB signaling
Daiki Kanaoka, Mitsuo Yamada, Hironori Yokoyama, et al.
Cancer Research Communications (2024)
Open Access | Times Cited: 3
N‐acetyltransferase 10 facilitates tumorigenesis of diffuse large B‐cell lymphoma by regulating AMPK/mTOR signalling through N4‐acetylcytidine modification of SLC30A9
Mengfei Ding, Zhuoya Yu, Tiange Lu, et al.
Clinical and Translational Medicine (2024) Vol. 14, Iss. 7
Open Access | Times Cited: 3
Page 1 - Next Page

Scroll to top